Skip to main content

Table 2 Frequency of microvascular and macrovascular complications by treatment

From: Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K

Complication Metformin (/100 pt) Combination (/100 pt) Improvement
    Absolute Relative (%)
Nephropathy     
Microalbuminuria 21.1 18.1 3.0 14.2
Gross proteinuria 18.8 13.4 5.4 28.7
End stage renal disease 5.9 4.4 1.5 25.4
Retinopathy     
Background retinopathy 30.7 23.7 7.0 22.7
Macular edema:     
Detected 25.4 20.6 4.7 18.7
Photocoagulated 24.3 19.9 4.5 18.4
Proliferative retinopathy:     
detected 12.3 7.9 4.5 36.3
photocoagulated 12.1 7.7 4.4 36.3
Blindness 9.4 8.0 1.4 14.9
Neuropathy     
Foot ulcer 21.1 16.3 4.8 22.7
Neuropathy 12.7 9.6 3.2 24.8
1st Lower-extremity amputation 9.0 7.5 1.5 16.5
2nd Lower-extremity amputation 5.1 4.3 0.7 14.6
Macrovascular Disease     
Myocardial infarction 15.0 14.6 0.4 2.4
Stroke 13.7 13.4 0.3 1.9